Algeta exercises full 50% co-promote option on Alpharadin
This article was originally published in Scrip
Executive Summary
Armed with promising clinical data, Algeta, the Norwegian cancer company, has told Bayer that it will exercise fully its co-promote option on Alpharadin (radium-223 chloride) to treat cancer patients with bone metastases in the US.